Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Graves' Disease
NCT06727604Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Dec 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of IMVT-1402 in Graves' disease, sponsored by Immunovant, Inc.. Started Dec 2024; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT06727604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727604.